Oncology: in Basilicata, patients are seen quickly and treatment begins within 16 days
The initial findings of the project evaluating the regional cancer network have been presented: high levels of patient satisfaction
Key points
To assess the quality of cancer care in order to identify strengths and opportunities for improvement in treatment pathways. This is the aim of the Val.Pe.ROB project – Evaluation of the Basilicata Oncology Network’s Care Pathways – carried out by the IRCCS CROB in collaboration with the Department of Business and Quantitative Studies (DISaQ) at the University of Naples Parthenope, through the Vimass research laboratory.
The initial results of the pilot project were presented at the Enzo Cervellino Auditorium of the IRCCS CROB in Rionero in Vulture, as part of an institutional conference dedicated to evaluating the performance of the Basilicata Oncology Network. The meeting brought together healthcare professionals, researchers and representatives from various institutions, providing an important opportunity to discuss the results achieved and future prospects for improving regional cancer care.
Val.Pe.ROB: measuring to improve cancer care
The project was launched with the aim of monitoring the quality and efficiency of care pathways within the Basilicata Oncology Network through the development of a multidimensional dashboard of key performance indicators (KPIs). The tool has been designed to assess various aspects of cancer care over time, integrating clinical, organisational and patient-experience dimensions. The aim is to provide healthcare decision-makers with useful information to support decision-making processes, identify any critical issues and promote the continuous improvement of services. Performance measurement is, in fact, a fundamental element of healthcare governance that is increasingly focused on quality, efficiency and placing the patient at the centre of the care pathway.
Treatment times and patient satisfaction: initial results
The pilot phase involved 70 patients with breast cancer between July 2024 and May 2025, analysing nine indicators relating to the duration of the care pathway and patient satisfaction. The results paint an encouraging picture, particularly with regard to the timeliness of treatment decisions. On average, 9 days elapse between the first consultation with the Multidisciplinary Oncology Team (MOT) and the finalisation of the treatment decision, whilst the average time between the decision and the start of treatment is 16 days.
Positive feedback has also emerged from patients’ experiences, with satisfaction levels ranging from 4.5 to 4.8 out of 5. The highest ratings relate to the quality of medical care, the attentiveness of healthcare staff and respect for privacy. This initial evidence provides an important knowledge base for consolidating the strengths of the care pathway and identifying further opportunities for improvement, through an approach based on the systematic measurement of outcomes.

